Clinical Value Analysis of Alprazolam Combined with Gastrodin in the Treatment of Neurasthenia  

作　　者：LIYanan 

机构地区：[1]Luoyang Rongkang Hospital, Luoyang He’nan 471000, China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第6期060-063,共4页

摘　　要：Objective: to explore the clinical effect of alprazolam combined with gastrodin on neurasthenia patients, and to improve their mental state and sleep quality. Methods: 100 patients with neurasthenia admitted to our hospital from July 2020 to July 2021 were selected as the research objects, and randomly divided into two groups. The control group was treated with alprazolam produced by Beijing Yimin Pharmaceutical Co., Ltd. and approved by Chinese medicine H11020890, while the research group was treated with gastrodin produced by Guangdong Sancaishiqi Pharmaceutical Co., Ltd. and approved by Chinese medicine H44021809. Results: after treatment, the effective rate of the study group was higher than that of the control group (P < 0.05). After treatment, the scores of SAS and SDS in the study group were lower than those in the control group before treatment. And the score of the study group was lower than that of the control group (P < 0.05). Before treatment, there was no statistical significance between the PSQI scores of the study group and the control group (P > 0.05). After treatment, the PSQI scores of both groups were lower than before treatment, and the scores of the study group were lower than those of the control group (P < 0.05). The treatment satisfaction of the study group was higher than that of the control group (P < 0.05). Conclusion: to investigate the abnormal mental state and poor sleep quality caused by neurasthenia, alprazolam combined with gastrodin can help patients to adjust their mental state and alleviate their poor sleep quality, which once again shows good effect.

关 键 词：NEURASTHENIA ALPRAZOLAM GASTRODIN mental state sleep quality 

分 类 号：R[医药卫生]